Overview
Adam Swank is an associate in the Securities and Capital Markets and Emerging Growth Companies practices and is based in the firm’s Century City office. His practice focuses on the representation of clients across the life sciences and technology industries, which include public and private companies, global investment banks, venture capital and growth equity funds. Adam advises clients in a variety of capital markets transactions including initial public offerings, follow-on offerings, at-the-market transactions and private placements of equity and debt securities. Adam also works with emerging growth companies and venture capital funds on a variety of capital raising transactions, including growth equity and debt financings. In addition, Adam counsels clients with their company formation matters, corporate governance, securities law compliance and periodic reporting requirements.
Adam received his law degree from UCLA School of Law in 2023 where he served as the chief managing editor of the UCLA Journal of Law and Technology. While in law school, Adam was a writing advisor and was inducted into the Moot Court Honors Program. He earned a Bachelor of Arts degree in Broadcast Journalism, cum laude, from Texas State University where he managed the university’s radio station.
Adam is admitted to practice law in California.
Representations
Initial Public Offerings and Follow-On Offerings
- J.P. Morgan Securities, Leerink Partners, Piper Sandler & Co. and William Blair & Company as underwriters in the $82 million initial public offering by CAMP4 Therapeutics Corporation
- Jefferies, J.P. Morgan Securities and the other underwriters in the $130 million follow-on offering and concurrent registered direct offering by ProKidney Corp.
- TD Securities, Cantor Fitzgerald & Co., Stifel, Nicolaus & Company and RBC Capital Markets in the $150 million follow-on offering by COMPASS Pathways plc.
- J.P. Morgan Securities as underwriter in the $285 million secondary offering by Harmony Biosciences
- Stifel, Nicolaus & Company, Truist Securities and the other underwriters in connection with the approximately $107 million U.S. initial public offering of TAT Technologies, an Israeli defense and aerospace manufacturer
- Jefferies as underwriter in the $90 million follow-on offering by Esperion Therapeutics
- Leerink Partners as underwriter in the approximately $80 million follow-on offering by PepGen Inc.
- Leerink Partners and Stifel, Nicolaus & Company as underwriters in Evolus Inc.’s $50 million follow-on offering
- TD Securities and WedBush PacGrow as underwriters in the $100 million follow-on offering by Monte Rosa Therapeutics
- TD Securities, Cantor Fitzgerald & Co., Barclays and other underwriters in multiple follow-on offerings by Humacyte, Inc., aggregating over $90 million
- Jefferies, Cantor Fitzgerald & Co. and the other underwriters in connection with Rezolute, Inc.’s approximately $60 million follow-on offering
- Stifel, Nicolaus & Company as underwriter in the $30 million follow-on offering by Precigen, Inc.
- Oppenheimer & Co. and Citizens JMP Securities as underwriters in Inovio Pharmaceutical’s approximately $36 million follow-on offering
- D.A. Davidson as underwriter in the approximately $25 million secondary offering by CPI Card Group
Venture Capital Financings
- Curbwaste in various financing transactions, including its $20 million Series B financing.
- Adam has represented a number of venture capital funds in connection with their investment activities, including Deerfield Management, Infinity Ventures, Digitalis Ventures, IAG Capital Partners and Guggenheim
At-the-Market Offerings
- Jefferies as sales agent in multiple at-the-market offering programs, including Achieve Life Sciences, Palladyne AI Corp., Corvus Pharmaceuticals, Vivani Medical, Inc., HOOKIPA Pharma, Valneva SE, Offerpad Solutions Inc., P3 Health Partners and Vuzix Corporation
- TD Securities as sales agent in several at-the-market offering programs, including COMPASS Pathways plc, Repare Therapeutics and Exscientia plc
- Leerink Partners as sales agent in the at-the-market offering programs for Harmony Biosciences and Lexeo Therapeutics
- Piper Sandler & Co. and Cantor Fitzgerald & Co. as sales agents in Arvinas Inc.’s $300 million at-the-market offering program
- Oppenheimer & Co. as sales agent in several at-the-market offering programs, including Inovio Pharmaceuticals, Y-mAbs Therapeutics and Climb Bio
- Stifel, Nicolaus & Company as sales agent in PepGen Inc.’s $100 million at-the-market offering program
Debt Financings
- Varonis Systems, Inc., a leader in data security, on its offering of $400 million of convertible senior notes and related capped call transactions
- TD Securities, BofA Securities, Goldman Sachs, Mizuho Securities and U.S. Bancorp as lead managers on an SEC-registered offering by TD Bank of $2 billion aggregate principal amount of its senior notes
- J.P. Morgan Securities and the other initial purchasers in Blackstone Mortgage Trust’s $450 million offering of senior secured notes